1. The VERITY Steering Committee
Third Venous Thromboembolism Registry Report 2005

2. Schematic of the report production process

3. List of contributors

4. List of contributors

5. List of contributors

6. Example table

7. Number of risk factors for patients with VTE (n=4,603)

8. Overview

9. Database overview

10. The growth of the database (n=27,179)

11. Data submitted by each centre

12. Number of risk factors and diagnosis

13. Number of risk factors for patients with VTE (n=4,603)

14. Final diagnosis and the number of risk factors (n=17,175)

15. Age distribution for all patients with VTE (n=27,123)

16. Final diagnosis over time (n=21,486)

17. Age and gender for patients with VTE

18. Age and gender for patients with VTE (n=6,045)

19. Age and gender for patients with VTE and Cancer (n=799)

20. Rates of different risk factors in patients who have VTE

21. Presence of various risk factors and final diagnosis

22. Task Force of the British Committee for Standards in Haematology13

23. D-dimer result and final diagnosis

24. Final diagnosis and D-dimer test (n=16,005)

25. D-dimer result, DVT pre-test probability and final diagnosis

26. Final diagnosis, D-dimer result, D-dimer test and DVT pre-test probability (n=11,585)

27. Suitability for home treatment1 amongst patients with confirmed DVT (n=5,371)

28. Reason patients with DVT were deemed unsuitable for home treatment; (patients unsuitable for home treatment with recorded reason n=466)

29. Duration of LMWH therapy and time to therapeutic INR in patients with DVT; patients receiving both treatments only (n=3,248)

30. Kaplan-Meier survival curves for patients with confirmed diagnosis of DVT and PE (n=2,224)

31. Pulmonary embolism

32. Primary and final diagnosis

33. Numbers of risk factors

34. Number of risk factors according to final diagnosis (n=4,603)

35. Different risk factors

36. Presence of selected risk factors for PE and non-PE patients

37. Age and disease

38. Age distributions according to final diagnosis (n=6,115)

39. A. Management of suspected non-massive pulmonary
A. Management of suspected non-massive pulmonary embolism with isotope lung scanning off site only

40. B. Management of suspected non-massive pulmonary
B. Management of suspected non-massive pulmonary embolism with isotope lung scanning available on site

41. PTP score and final diagnosis

42. PTP score distributions for patients with confirmed PE and non-PE patients (n=279 and n=342 respectively)

43. PTP score distributions for patients with confirmed PE and non-PE patients (n=279 and n=342 respectively)

44. PTP score D-dimer and final diagnosis

45. Using <4 and ≥4 to classify the PE PTP score
Final diagnosis, D-dimer results and PE PTP score for patients with a suspected PE (n=438)
Using <4 and ≥4 to classify the PE PTP score

46. Using <2,2-6 and >6 to classify the PE PTP score
Final diagnosis, D-dimer results and PE PTP score for patients with a suspected PE (n=438)
Using <2,2-6 and >6 to classify the PE PTP score

47. Other investigations performed

48. Investigations performed and diagnosis

49. Chest x-ray

50. The Royal Perth Hospital algorithm

51. Treatment of patients with PE – location of treatment

52. Suitability of PE patients for home treatment1 (n=457)

53. Doses of LMWH

54. Average number of doses of LMWH for non-PE and PE patients; bars denote standard error

55. Prediction of the risk of adverse events in PE patients

56. Thromboprophylaxis

57. Source of referral for medical inpatients with VTE

58. Source of referral for surgical inpatients with VTE

59. Source of referral for patients with a history of surgical inpatient stay and VTE (n=685)

60. Final diagnosis and inpatient history - Overview

61. Final diagnosis and inpatient history

62. Focus on medical inpatient history

63. Medical inpatient history for each final diagnosis (n=21,080)

64. Focus on surgical inpatient history

65. Surgical inpatient history for each final diagnosis (n=20,996)

66. Speciality for VTE patients who have recently had surgery (n=685)

67. Thromboprophylaxis provision for VTE patients (n=3,189)

68. Source of referral and the use of thromboptophylaxis for VTE patients (n=3,580)

69. Trends in the use of LMWH as thromboprophylasis for VTE patients (n=730)

70. Thromboprophylaxis and surgical speciality for VTE patients

71. Thromboprophylaxis provision and surgical speciality for VTE patients (n=603)

72. Thromboprophylaxis and inpatient stay

73. Type of thromboprophylaxis, final diagnosis and inpatient history

74. Thromboprophylaxis and risk factors in medical inpatients with VTE

75. Final diagnosis and new risk score

76. Final diagnosis of VTE and weighted risk score (n=5,692)

77. Thromboprophylaxis and the weighted score

78. Thromboprophylaxis and weighted risk score (n=4,794)

79. Kaplan-Meier survival curves for patients with confirmed diagnoses of DVT according to recent medical inpatient history (n=242 and n=1,883 respectively)

80. Kaplan-Meier survival curves for patients with confirmed diagnoses of DVT according to recent surgical inpatient history (n=266 and n=1,839 respectively)

81. Number of referrals over time according to patients’ history and Percentage of patients with confirmed VTE over time according to patients’ history

82. Number of referrals over time according to patients’ history and Percentage of patients with confirmed VTE over time according to patients’ history

83. VTE and Cancer

84. Cancer rates amongst VTE patients at each hospital

85. Final diagnosis and cancer

86. Presence of a final diagnosis of VTE in cancer and non-cancer patients

87. Cancer, age and gender in patients with VTE

88. Cancer rates broken down by age and gender for patients with VTE (n=5,655)

89. Specific type of cancer and age for patients with VTE

90. Specific type of cancer and age for patients with VTE

91. Cancer rates broken down by age for the most frequently occuring cancers in VERITY amongst patients with VTE (n=5,582)

92. Specific type of cancer and final diagnosis

93. Type of cancer and final diagnosis (n=1,205)

94. D-dimer and cancer

95. D-dimer results in the context of cancer (n=15,240)

96. Location of treatment

97. Location of treatment and cancer for VTE patients (n=5,480)

98. Doses of LMWH

99. Duration of LMWH therapy and time to therapeutic INR in patients with DVT in the context of cancer; patients receiving both therapies only (n=3,444)

100. Duration of LMWH therapy in patients with VTE in the context of cancer (n=4,138)

101. Kaplan-Meier survival curves for patients with confirmed diagnoses of VTE according to the presence of absence of cancer (n=2,224)

102. Walsgrave hospital: Cancer and medium-term mortality in VTE patients

103. VTE and Pregnancy

104. Final diagnosis and pregnancy

105. Final diagnosis and pregnancy (n=12,336)

106. Risk factors and pregnancy

107. Final diagnosis and pregnancy (n=3,389)

108. Final diagnosis and selected risk factors amongst pregnant patients

109. Investigations and pregnancy

110. Investigations in pregnant patients

111. Treatment and pregnancy – use of LMWH

112. LMWH use and final diagnosis for pregnant patients (n=378)

113. Doses of LMWH

114. LMWH doses and final diagnosis for pregnant patients; bars denote standard errors (n=89 and 50 respectively)

115. Warfarin therapy and post partum

116. Warfarin use and final diagnosis for post partum patients (n=425)

117. Summary of protocol for thromboprophylaxis in women with previous VTE and / or thrombophiliai

118. A clinical model for predicting pre-test probability for deep vein thrombosisi

119. Variables used to determine a pre-test probability score in patients with suspected pulmonary embolismii

120. A new weighted score to determine the risk of VTEiii